BMY

Bristol-Myers Squibb Company Healthcare - Pharmaceuticals Investor Relations →

NO
9.1% ABOVE
↓ Approaching Was 12.1% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $52.69
14-Week RSI 62
Rel. Volume (14w) This week's trading vs. the 14-week average 1.8x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.23

Bristol-Myers Squibb Company (BMY) closed at $57.48 as of 2026-03-20, trading 9.1% above its 200-week moving average of $52.69. The stock is currently moving closer to the line, down from 12.1% last week. The 14-week RSI sits at 62, indicating neutral momentum.

Trading volume is running at 1.8x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.23 ratio) is neutral — neither side is clearly dominating.

Over the past 2759 weeks of data, BMY has crossed below its 200-week moving average 29 times. On average, these episodes lasted 25 weeks. Historically, investors who bought BMY at the start of these episodes saw an average one-year return of +4.4%.

With a market cap of $117.1 billion, BMY is a large-cap stock. The company generates a free cash flow yield of 9.5%, which is notably high. Return on equity stands at 40.4%, indicating strong profitability. The stock trades at 6.3x book value.

Over the past 33.2 years, a hypothetical investment of $100 in BMY would have grown to $1333, compared to $2683 for the S&P 500. BMY has returned 8.1% annualized vs 10.4% for the index, underperforming the broader market over this period.

Free cash flow has been growing at a 2.4% compound annual rate, with 4 consecutive years of positive cash generation.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: BMY vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After BMY Crosses Below the Line?

Across 22 historical episodes, buying BMY when it crossed below its 200-week moving average produced an average return of -1.8% after 12 months (median +3.0%), compared to +8.3% for the S&P 500 over the same periods. 52% of those episodes were profitable after one year. After 24 months, the average return was -10.1% vs +14.2% for the index.

Each line shows $100 invested at the moment BMY crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Historical Touches

BMY has crossed below its 200-week MA 29 times with an average 1-year return of +4.4% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
May 1973Jul 1973911.7%-16.5%+20485.2%
Aug 1973Jan 19757743.4%-22.2%+19602.1%
Feb 1978Mar 197833.3%+16.7%+17926.7%
Mar 1978Apr 197810.9%+19.8%+17926.7%
Oct 1978Oct 197812.8%+9.2%+17004.5%
Jul 1979Jul 197910.6%+31.5%+15972.7%
Mar 1980Mar 198032.3%+83.2%+15909.1%
Jan 1993Jan 199510517.8%+2.3%+1222.1%
Jul 2000Aug 200051.4%+14.0%+215.5%
Sep 2000Sep 200010.2%+16.4%+205.8%
Apr 2001Jul 2001138.4%-43.3%+179.3%
Sep 2001Sep 200117.3%-51.0%+189.4%
Oct 2001Nov 200123.9%-50.8%+177.0%
Nov 2001Feb 200622060.4%-48.9%+173.3%
Aug 2006Aug 2006310.7%+48.3%+490.5%
Jan 2008Dec 20084722.5%+3.3%+388.9%
Jan 2009Jul 20092817.9%+20.1%+380.3%
Oct 2016Nov 201646.6%+34.7%+59.7%
Jan 2017Feb 2017512.5%+29.9%+60.4%
Mar 2017Jul 2017184.0%+19.5%+45.2%
Apr 2018Jul 20181511.3%-8.3%+49.3%
Oct 2018Oct 20195421.1%-7.2%+31.0%
Mar 2020Mar 202029.7%+33.7%+49.4%
Jul 2023Aug 202331.9%-13.8%+5.5%
Sep 2023Nov 20246333.0%-16.0%+6.5%
Dec 2024Jan 202562.8%-1.4%+9.4%
Feb 2025Feb 202535.3%+14.5%+6.2%
Mar 2025Dec 20253719.4%N/A+9.2%
Dec 2025Jan 202610.2%N/A+8.8%
Average25+4.4%

Frequently Asked Questions

Is BMY below its 200-week moving average?

No. Bristol-Myers Squibb Company (BMY) is currently 9.1% above its 200-week moving average of $52.69. It would need to fall to $52.69 to cross below the line.

What is BMY's 200-week moving average price?

Bristol-Myers Squibb Company's 200-week moving average is $52.69 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when BMY drops below its 200-week moving average?

BMY has crossed below its 200-week moving average 29 times in our data. On average, buying at that moment produced a one-year return of +4.4%. These dips have historically been decent entry points. These episodes lasted 25 weeks on average.

Is BMY a good value right now?

Here's what our data says about BMY as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 62. Free cash flow yield is 9.5%. Return on equity is 40.4%. Price-to-book is 6.3x. This is not a buy or sell recommendation — always do your own research.

How does BMY compare to the S&P 500?

Over the past 33.2 years, $100 invested in BMY would have grown to $1333, compared to $2683 for the S&P 500. That's 8.1% annualized vs 10.4% for the index. BMY has underperformed the broader market over this period.

Does BMY pay a dividend?

Yes. Bristol-Myers Squibb Company currently pays a dividend yield of 438.00%.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-03-20